Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion
10 December 2020 – Walder Wyss advises Boehringer Ingelheim in the acquisition of NBE-Therapeutics AG. NBE-Therapeutics is a private Basel based clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.
The total transaction value is EUR 1.18 billion and also includes contingent clinical and regulatory milestones.
The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.
The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and included Robert Desax (Partner, Tax), Jessica Aeschbach Flórez (Senior Associate, Corporate/M&A), Karina Tschon (Associate, Corporate/M&A and Venture Capital), Flurin Vionnet-Riederer (Associate, Corporate/M&A), Christoph Burckhardt (Associate, Corporate/M&A) and Jonas Knechtli (Senior Associate, Employment).